Ossiam Boosts Stock Position in Pfizer Inc. $PFE

Key Points

• Ossiam increased its Pfizer stake by 71.2% in Q2, buying 2,349,058 shares to hold 5,650,573 shares (about 0.10% of Pfizer) valued at $136.97 million, making PFE its 11th-largest position and ~1.5% of the fund's portfolio.
• Pfizer topped quarterly EPS estimates ($0.87 vs. $0.79) and set FY2025 guidance of 3.000–3.150 EPS, versus analysts' consensus near 2.95 EPS.
• Pfizer pays a quarterly dividend of $0.43 (annualized $1.72) for a 6.6% yield with a 100% payout ratio, while the analyst consensus is a "Hold" with an average price target of $28.39.

Ossiam increased its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 71.2% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,650,573 shares of the biopharmaceutical company's stock after purchasing an additional 2,349,058 shares during the period. Pfizer makes up about 1.5% of Ossiam's investment portfolio, making the stock its 11th largest position. Ossiam owned about 0.10% of Pfizer worth $136,970,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of PFE. Westbourne Investments Inc. purchased a new position in Pfizer during the first quarter worth $2,411,000. Bourne Lent Asset Management Inc. grew its stake in shares of Pfizer by 90.8% during the second quarter. Bourne Lent Asset Management Inc. now owns 38,255 shares of the biopharmaceutical company's stock valued at $927,000 after buying an additional 18,200 shares during the last quarter. Strs Ohio purchased a new stake in shares of Pfizer in the first quarter worth approximately $49,968,000. IFM Investors Pty Ltd lifted its stake in shares of Pfizer by 3.8% during the 2nd quarter. IFM Investors Pty Ltd now owns 1,127,143 shares of the biopharmaceutical company's stock worth $27,322,000 after acquiring an additional 41,263 shares during the last quarter. Finally, Intrua Financial LLC lifted its stake in shares of Pfizer by 17.4% during the 1st quarter. Intrua Financial LLC now owns 78,392 shares of the biopharmaceutical company's stock worth $1,986,000 after acquiring an additional 11,643 shares during the last quarter. Institutional investors own 68.36% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages have commented on PFE. Bank of America upped their price objective on Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday, October 3rd. Citigroup started coverage on shares of Pfizer in a research note on Tuesday, December 2nd. They set a "neutral" rating and a $26.00 target price for the company. Wall Street Zen downgraded shares of Pfizer from a "buy" rating to a "hold" rating in a research note on Sunday, September 28th. Morgan Stanley decreased their price objective on shares of Pfizer from $33.00 to $32.00 and set an "equal weight" rating for the company in a report on Friday, October 10th. Finally, UBS Group restated a "neutral" rating and issued a $28.00 target price on shares of Pfizer in a research note on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $28.39.

Pfizer Stock Performance

PFE stock opened at $26.03 on Monday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.69. The business has a 50-day moving average price of $25.17 and a 200 day moving average price of $24.69. The company has a market capitalization of $147.97 billion, a P/E ratio of 15.13 and a beta of 0.46. The company has a debt-to-equity ratio of 0.62, a current ratio of 1.28 and a quick ratio of 0.97.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.87 earnings per share for the quarter, topping analysts' consensus estimates of $0.79 by $0.08. The company had revenue of $16.65 billion during the quarter, compared to analyst estimates of $16.94 billion. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. Pfizer has set its FY 2025 guidance at 3.000-3.150 EPS. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Monday, December 1st. Investors of record on Friday, November 7th were issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.6%. The ex-dividend date of this dividend was Friday, November 7th. Pfizer's dividend payout ratio (DPR) is presently 100.00%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.